Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Buy Rating from Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $210.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 53.90% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $184.47.

Jazz Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ:JAZZ opened at $136.45 on Wednesday. The stock’s 50-day moving average price is $127.85 and its two-hundred day moving average price is $119.83. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $148.06. The firm has a market cap of $8.29 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 1.04 and a beta of 0.56.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,113 shares of company stock worth $2,551,834. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors have recently modified their holdings of JAZZ. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after buying an additional 507,234 shares during the period. Darwin Global Management Ltd. acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at $59,668,000. Dimensional Fund Advisors LP lifted its holdings in shares of Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after buying an additional 320,724 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after buying an additional 315,608 shares during the period. Finally, GMT Capital Corp lifted its holdings in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after buying an additional 296,800 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.